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Abstract Hospital-acquired pneumonia (HAP) and com-
munity-acquired pneumonia (CAP) are among the most
common infections treated in the hospital setting, and
together they place a significant burden on healthcare
systems. Successful management of HAP and CAP
depends on rapid initiation of empirical antibiotic therapy
with broad-spectrum antibiotics. Ceftobiprole is a new-
generation, broad-spectrum cephalosporin antibiotic for the
treatment of HAP (excluding ventilator-associated pneu-
monia) and CAP. It displays potent in vitro activity against
a broad range of pathogens important in pneumonia. This
review summarizes the pharmacokinetic profile of cefto-
biprole, and considers the pharmacokinetic parameters and
pharmacodynamics underlying the choice of dosing regi-
men. Ceftobiprole shows linear pharmacokinetics after
single and multiple doses and is eliminated predominantly
through the kidneys. Ceftobiprole is administered as a
500 mg intravenous infusion over 2 h every 8 h, and
steady-state concentrations are reached on the first day of
dosing. Dose adjustment is recommended for patients with
moderate or severe renal impairment and for those with
end-stage renal disease. Extending the infusion time of
ceftobiprole to 4 h is recommended to optimize drug
exposure in critically ill patients with augmented renal
clearance. However, there is no need for dose adjustments
based on age, sex or ethnicity, or for patients with severe
obesity. Population pharmacokinetic modelling and Monte
Carlo simulations were used to determine the optimal
dosing regimen for ceftobiprole in special patient popula-
tions, including paediatric patients. Future studies of
ceftobiprole in patients with HAP and CAP would be of
interest.
Key Points
Ceftobiprole is a new-generation cephalosporin
antibiotic for the treatment of hospital-acquired
pneumonia (excluding ventilator-associated
pneumonia) and community-acquired pneumonia.
Ceftobiprole is administered as a 500 mg infusion
over 2 h every 8 h. No dose adjustments are required
based on sex, ethnicity or age, or for patients with
hepatic impairment or severe obesity.
Ceftobiprole is eliminated predominantly through
the kidneys. Dose adjustment is recommended for
patients with moderate or severe renal impairment
and for patients with end-stage renal disease; as for
all b-lactams, for patients with augmented renal
clearance, extending the infusion time up to 4 h may
help to optimize ceftobiprole exposure.
& Antonio Torres
atorres@ub.edu
1 Department of Pulmonology, Hospital Clinic of Barcelona,
CIBERES, IDIBAPS, University of Barcelona, Villarroel
170, 08036 Barcelona, Spain
2 Erasmus MC, Rotterdam, The Netherlands
3 Radboud University Medical Center Nijmegen, Nijmegen,
The Netherlands
4 Institute of Clinical Pharmacology, Azienda Ospedaliero-
Universitaria Santa Maria della Misericordia, Udine, Italy
5 Department of Experimental and Clinical Medical Sciences,
University of Udine, Udine, Italy
Clin Pharmacokinet (2016) 55:1507–1520
DOI 10.1007/s40262-016-0418-z
1 Introduction
The burden of illness associated with pneumonia is con-
siderable, both in terms of patient morbidity/mortality and
the use of healthcare resources. Hospital-acquired pneu-
monia (HAP) occurs in approximately 3–10 of every 1000
hospital admissions, making it one of the most common
nosocomial infections [1, 2]. HAP is associated with
increases in the length of hospital stay and additional
healthcare costs, and therefore has a marked impact on
healthcare resource use [3, 4].
Community-acquired pneumonia (CAP; pneumonia
acquired outside a hospital setting or an extended-care
facility) is a considerable cause of morbidity and mortality
[5]. Annual incidences of 5–11 cases per 1000 population
have been reported in studies in Europe and the US, and up
to 60 % of these individuals can require hospital treatment
[6, 7]. Among patients hospitalized with CAP, mortality is
significant, with rates of up to 14 % [5, 7]. The impact of
CAP on healthcare resources is also considerable; the costs
of hospitalization are a high proportion of the overall costs
of care, with length of hospital stay being a major factor
[6].
In HAP, Gram-negative pathogens are the most frequent
cause of infection, with Pseudomonas aeruginosa, Acine-
tobacter baumannii (although not in Northern Europe),
Escherichia coli, and Klebsiella and Enterobacter species
all commonly isolated from patients [8, 9]. Gram-positive
pathogens such as Staphylococcus aureus (including
methicillin-resistant S. aureus [MRSA]) and Streptococcus
pneumoniae are also detected, albeit less frequently
[8, 9]. S. pneumoniae is the most commonly identified
cause of CAP; other commonly isolated pathogens include
Haemophilus influenzae and S. aureus [5–7].
The successful management of HAP and CAP depends
on rapid and adequate empirical antibiotic therapy. A range
of factors are taken into consideration when choosing a
treatment, including suspected pathogens, patterns of local
antibiotic resistance, illness severity and patient risk factors
[7, 9, 10]. Effective treatment relies on broad-spectrum
antibiotics that generate rapid effects.
Ceftobiprole is a new-generation, broad-spectrum
cephalosporin approved in 13 European countries and in
Canada for the treatment of HAP (excluding ventilator-
associated pneumonia [VAP]) and CAP [11–13]. The aims
of this review were to summarize the pharmacokinetic
profile of ceftobiprole in healthy individuals and patients,
examine the pharmacokinetic parameters and pharmaco-
dynamics underlying the choice of dosing regimen, and
consider the pharmacokinetics and dosing of ceftobiprole
in special patient populations, including critically ill
patients treated in an intensive care unit (ICU), and those
with renal impairment. Papers reporting the pharmacoki-
netics of ceftobiprole were identified from PubMed sear-
ches, using terms including BAL5788, ceftobiprole/
ceftobiprole medocaril, pneumonia and pharmacokinetic/
pharmacokinetics. References were screened by title and
abstract to identify potentially relevant articles; the bibli-
ographies of appropriate papers were also screened to
identify further studies for inclusion. In addition, relevant
abstracts presented at the European Congresses of Clinical
Microbiology and Infectious Diseases (ECCMID) for
2004–2016 and Annual Interscience Conferences on
Antimicrobial Agents and Chemotherapy (ICAAC) for
2004–2015 were identified.
2 Ceftobiprole Overview
Ceftobiprole is the active moiety of the prodrug cefto-
biprole medocaril. The recommended dose in adults with
normal renal function is ceftobiprole 500 mg, administered
as a 2-h intravenous infusion every 8 h [14, 15]. Dose
adjustments are recommended according to renal function,
as described in detail below (see Sect. 5 for further details)
[14].
Ceftobiprole has shown antimicrobial activity in vitro
against a broad range of pathogens important in pneumo-
nia, including Gram-positive pathogens, such as MRSA, S.
pneumoniae and Enterococcus faecalis, and Gram-negative
pathogens, such as H. influenzae and P. aeruginosa
[11, 16–18]. Findings from two randomized, double-blind,
phase III clinical studies have demonstrated the efficacy of
ceftobiprole in patients with HAP (excluding VAP) or CAP
[19, 20]. In 781 patients with HAP, ceftobiprole (500 mg
every 8 h) demonstrated non-inferiority to ceftazidime (2 g
every 8 h) plus linezolid (600 mg every 12 h) for the pri-
mary efficacy measure of clinical cure rate at the test-of-
cure (TOC) visit [19]. In addition, ceftobiprole showed
non-inferiority to the combination for clinical cure in
patients with HAP (excluding VAP), but not in patients
with VAP alone [19]. Ceftobiprole was efficacious for the
treatment of HAP associated with Gram-positive patho-
gens, such as S. aureus and MRSA, and with Gram-nega-
tive pathogens, such as P. aeruginosa [19]. In 706 patients
hospitalized with CAP, ceftobiprole (administered as
above) was non-inferior to ceftriaxone (2 g every 24 h)
with or without linezolid (administered as above) for the
same primary efficacy measure [20]. Ceftobiprole treat-
ment was generally well tolerated in both phase III studies
[19, 20]. The efficacy of ceftobiprole for the treatment of
HAP has been reviewed in detail by Scheeren [13].
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3 Overall Pharmacokinetic Profile of Ceftobiprole
in Healthy Individuals
The pharmacokinetics of ceftobiprole following single- and
multiple-dose administration have been assessed in several
studies in healthy individuals [15, 21, 22]. The prodrug
ceftobiprole medocaril was rapidly converted, probably by
type A esterases, to the active substance ceftobiprole fol-
lowing 30-min intravenous infusion [23, 24]. Peak plasma
concentrations were reached at the end of the infusion,
while the following biphasic decrease reflected the rapid
distribution [half-life (t) in the distribution phase,
0.57 ± 0.22 min] of ceftobiprole into other body com-
partments. Ceftobiprole exhibited linear pharmacokinetics
after single- or multiple-dose administration over the dose
range 125–1000 mg [23–25]. In addition, ceftobiprole
pharmacokinetics were shown to be time-independent [15].
Steady-state concentrations were attained rapidly within
the first day of dosing [14]; accumulation with multiple
dosing every 8 h was minimal in healthy individuals with
normal renal function [15].
The main pharmacokinetic parameters for ceftobiprole
in healthy individuals following a single 500 mg dose
administered by 2-h intravenous infusion are shown in
Table 1 [26], together with the pharmacokinetic data for
other cephalosporin antibiotics commonly used in HAP and
CAP [14, 26–35]. The pharmacokinetics observed after
multiple-dose administration of ceftobiprole 500 mg every
8 h were similar to those seen with a single dose [26].
Systemic exposure [area under the plasma concentration–
time curve from time zero to 8 h (AUC8)] and maximum
plasma concentration (Cmax) on day 5 were similar to those
observed on day 1 of dosing (AUC8, 102 ± 11.9 and
90.0 ± 12.4 mg h/L, respectively; Cmax, 33.0 ± 4.83 and
29.2 ± 5.52 mg/L, respectively), while values for renal
clearance (CLR), total systemic clearance (CLT) and
elimination half-life (t) were virtually unchanged on days
1 and 5 (CLR, 4.28 ± 0.57 and 4.08 ± 0.72 L/h, respec-
tively; CLT, 4.98 ± 0.58 and 4.89 ± 0.69 L/h, respec-
tively; t, 3.3 ± 0.3 and 3.1 ± 0.3 h, respectively)
[15, 26]. The mean volume of distribution at steady state
(VSS) with ceftobiprole was 29 % lower on day 5 compared
with day 1 (15.5 ± 2.33 vs. 21.7 ± 3.3 L). The VSS was
similar to the volume of the extracellular fluid compart-
ment in adults, consistent with findings seen with other b-
lactam agents [26]. Protein binding with ceftobiprole
(16 %) [14] was consistent with the values reported for
ceftaroline (*20 %) [32], ceftazidime (10–23 %)
[33, 36, 37] and cefepime (*20 %) [34], whereas higher
values have been reported for cefotaxime (37 %) [35]
(Table 1). High concentration-dependent plasma protein
binding has been shown for ceftriaxone (41–99 %)
[38, 39]. The half-life of ceftobiprole was approximately
3 h, which was comparable to that for ceftaroline. Cef-
tazidime, cefepime and cefotaxime had shorter half-lives
(1.95, 2.00 and 1.04 h, respectively), whereas ceftriaxone
had a longer half-life (6.30 h) [28, 40] (Table 1).
Penetration of ceftobiprole into lung tissue, as measured
by concentrations in the epithelial lining fluid (ELF), was
assessed in healthy individuals at a presumed steady state
(following the fourth dose of ceftobiprole) [41]. This
showed that mean ceftobiprole concentrations in the ELF
were lower than in the plasma over the 8 h following the
start of infusion. Population pharmacokinetic modelling
based on these data showed that mean penetration into the
ELF was 25.5 % (median 15.3 %; interquartile range
7.9–30.4 %; calculated from the ratio of ELF/total cefto-
biprole) [41]. In the murine model of pneumonia, lung
penetration of ceftobiprole, based on AUC values in the
ELF and plasma, was higher (median 68.8 %) than in
healthy individuals [41]. However, the measured ELF
levels of antibiotics may not accurately predict b-lactam
concentrations at the site of infection [42], especially in
studies in healthy volunteers.
A review of clinical studies comparing the ELF con-
centrations of ceftobiprole with those of other cephalos-
porins showed that lung penetration with the majority of
agents was similar to that observed with ceftobiprole [43].
For most of the oral or parenteral cephalosporins studied,
the percentage lung penetration, calculated from the ratio
of ELF to total plasma concentrations, ranged from 10 to
38 % [43]. Similarly, the lung penetration of ceftazidime
(4 g/day) was 21 % in a study in 15 adults with HAP who
were receiving mechanical ventilation [44]. However,
higher values were reported with cefepime during contin-
uous intravenous infusion (4 g/day) in patients with severe
nosocomial pneumonia [45]. After 2 days of therapy,
cefepime showed similar concentrations in the ELF and
plasma, giving a mean penetration of approximately 100 %
[46]. It is currently unclear what impact an infection may
have on ceftobiprole lung penetration in humans [41].
The penetration of ceftobiprole into soft tissue and
bone has also been examined. Following a single 2-h
infusion of ceftobiprole 500 mg in healthy volunteers,
ceftobiprole systemic exposure and peak concentrations
(measured using in vivo microdialysis) were lower in both
skeletal muscle and subcutaneous adipose tissue than in
plasma [mean penetration: 69 % for skeletal muscle and
49 % for adipose tissue (calculated as tissue-to-plasma
AUC ratios for free drug)] [47], which is in line with
values reported for other cephalosporins. In adults
receiving ceftobiprole 500 mg as a 2-h intravenous infu-
sion before undergoing total hip replacement surgery,
ceftobiprole exposure in cortical bone was almost 3.5-fold
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higher than that in cancellous bone [48]. Bone penetration
of ceftobiprole (the ratio of AUC in bone relative to that
in unbound plasma) was 0.22 for cortical bone and 0.06
for cancellous bone (0.15–0.3) [49]. In a rabbit model of
tibial osteomyelitis, after ceftobiprole treatment for
4 weeks, bacterial titres in the infected tibia were below
the limit of detection in all of the evaluable animals,
compared with 73 % of those animals treated with either
vancomycin or linezolid [50].
Elimination of ceftobiprole occurs predominantly
through renal excretion [15, 26]. With multiple dosing,
approximately 80–90 % of the administered dose is
recovered in the urine as unchanged ceftobiprole [15, 23].
Elimination occurs mainly by glomerular filtration, and
does not involve active tubular secretion [15]. Renal drug-
drug interactions are therefore not expected with cefto-
biprole [11]. The linear relationship between systemic and
renal clearance observed for ceftobiprole allows the
Table 1 Single-dose pharmacokinetic parameters and EUCAST clinical breakpoints for ceftobiprole and other cephalosporins
Parameter Ceftobiprole
500 mg
[15, 24, 26]
Ceftazidime
1000 mg
[27, 33, 67]
Ceftriaxone
500 mg
[28, 40]
Ceftaroline
600 mg
[30, 32]
Cefotaxime
500 mg
[31, 35, 74]
Cefepime
500 mg
[29, 34]
Pharmacokinetic parameters following single-dose administration in healthy individuals
Number of patients 28 15a 12 6b 9
Infusion time (min) 120 30 30 60 5 30
Cmax (mg/L) 29.2 ± 5.52 86.29 ± 13.06 82.0 ± 10.4 28.4 ± 7.0 37.9 ± 2.1 31.9 ± 6.0
tmax (h) – – 0.5 1.0 – –
AUC? (mgh/L) 104 ± 13.9 150.30 ± 19.84 551 ± 91 75.6 ± 9.7 30.6 ± 2.2 56.6 ± 11.4
t for the distribution phase
(h)
– – 0.21c – 0.19 ± 0.03 –
t for the post-distribution
phase (h)
3.1 ± 0.3 1.95 ? 0.25 6.30c 2.9 ± 0.4 1.04 ± 0.07 2.00 ± 0.64
Vd 21.7 ± 3.3 L 0.21 ± 0.03 L/kg 8.46 ± 1.11 L 29.3 ± 5.2 L
d 19.1 ± 1.2
L/1.73 m2
18.3 ± 1.9 L
CLT 4.89 ± 0.69
L/h
0.095 ± 0.014
L/h/kg
0.929 ± 0.15
L/h
7.11 ± 0.89
L/he
14.72 ± 1.17 L/h/
1.73 m2
9.12 ± 1.68
L/h
CLR 4.08 ± 0.72
L/h
0.084 ± 0.014
L/h/kg
0.373 ± 0.60
L/h
3.36 ± 0.83
L/h
8.81 ± 1.12 L/h/
1.73 m2
8.28 ± 1.98
L/h
Urinary excretion (%)f 83.1 ± 9.06 88.26 ± 5.50 38 ± 7g [28]
(*60 %) [42]
46.8 ± 6.1 58.8 91.0 ± 15.2
Protein binding (%) 16 10–23 41–99 *20 37 *20
EUCAST MIC breakpoints (SB/R[) [75]
Staphylococcus aureus 2/2 ND NDh 1/1 NDh NDh
Streptococcus pneumoniae 0.5/0.5 ND 0.5/2 0.25/0.25 0.5/2 1/2
Enterobacteriaceae 0.25/0.25 1/4 1/2 0.5/0.5 1/2 1/4
Pseudomonas aeruginosa IE 8 ND ND ND 8
Data are expressed as mean ± standard deviation or mean ± standard error (cefotaxime), except for tmax, which is expressed as median
AUC? area under the plasma concentration–time curve from time zero extrapolated to infinity, Cmax maximum plasma concentration, CLCR
creatinine clearance, CLR renal clearance, CLT total systemic clearance, EUCAST European Committee on Antimicrobial Susceptibility Testing,
Fm fraction of the dose metabolized, IE insufficient evidence, MIC minimum inhibitory concentration, ND breakpoint not defined (susceptibility
testing not recommended), R resistant, S susceptible, t half-life, tmax time to Cmax, Vd volume of distribution, Vz volume of distribution based on
the terminal phase
a Mean weight 72.0 kg
b Individuals with normal renal function (CLCR[ 80 mL/min)
c Harmonic mean
d Vz/Fm, volume of distribution based on the terminal phase/fraction of the dose metabolized
e CL/Fm, plasma clearance/fraction of the dose metabolized
f Unchanged drug over 24 h
g n = 11
h Susceptibility can be inferred from cefoxitin testing (S B/R[,[4 mg/L)
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accurate prediction of dose modification for patients with
renal impairment (as discussed in Sect. 5.1 below) [51].
3.1 Role of Pharmacokinetic Characteristics
in the Tolerability of Ceftobiprole
The predominantly renal elimination observed with cefto-
biprole is typical of most cephalosporins. For example,
ceftazidime [27], cefepime [29] and ceftaroline [32] are
eliminated mainly via the kidneys. By contrast, ceftriaxone
shows substantial elimination via non-renal pathways,
through biliary excretion into the gut [28]. In regard to drug
tolerability, one potential benefit of renal elimination is that
it may limit antibiotic exposure in the gut, although to date
there are no studies that specifically address this. Cefto-
biprole has shown no significant effect on the intestinal
microflora of healthy individuals [52] and was generally
well tolerated in clinical studies [19, 20]. Over a 3-week
study period, no measurable concentrations of ceftobiprole
were found in the faeces of healthy individuals who
received intravenous infusions of ceftobiprole 500 mg
every 8 h for the first 7 days. The lack of ceftobiprole in
the intestine is thought to account for the minor effects on
intestinal microflora. In addition, no new colonizing
ceftobiprole-resistant aerobic or anaerobic bacteria were
detected among the intestinal microflora, and no Clostrid-
ium difficile strains or toxins were found [52]. Furthermore,
a study in mice showed that ceftobiprole did not promote
the growth of C. difficile in caecal contents, whereas cef-
tazidime, cefoxitin, ceftriaxone, cefotaxime and ertapenem
all promoted significant C. difficile growth when compared
with saline controls, and were associated with toxin pro-
duction [53].
Finally, ceftobiprole treatment was generally well tol-
erated in the phase III clinical studies in patients with HAP
or CAP [19, 20]. The incidence of treatment-related
adverse events was similar to that with other cephalos-
porins, with the most frequent being hyponatraemia, diar-
rhoea, nausea and phlebitis [19].
4 Pharmacokinetic/Pharmacodynamic
Relationships and Dosing Considerations
for Ceftobiprole
For b-lactam antibacterial agents, duration of exposure is
the key factor in determining therapeutic efficacy. The
main pharmacokinetic/pharmacodynamic index shown to
correlate with therapeutic efficacy is the length of time that
the unbound drug concentration exceeds the minimum
inhibitory concentration (fT[MIC), typically expressed
as a proportion of the dosing interval (%fT[MIC) [54].
An appropriate dosing regimen can be determined based on
a suitable %fT[MIC target once the dose-effect rela-
tionships have been established for a particular drug
[55, 56].
Non-clinical studies in animals have shown a strong
correlation between %fT[MIC and efficacy for cefto-
biprole. The %fT[MIC values required for the static
doses were 36–45 % for Enterobacteriaceae, 14–28 % for
S. aureus and 15–22 % for S. pneumoniae [57]. Based on
findings from the in vivo murine pneumonia and thigh
infection models, the most appropriate pharmacodynamic
targets chosen for ceftobiprole dose selection analyses
were a %fT[MIC of 30 % for documented Gram-positive
infections and 50 % for broad-spectrum coverage of both
Gram-positive and Gram-negative pathogens; a
%fT[MIC of 50 % was used to determine the European
Committee on Antimicrobial Susceptibility Testing
(EUCAST) non-species-specific breakpoint (4 mg/L)
[15, 22, 58] as this is the exposure correlated with a 1- to
2-log10 kill.
The knowledge gained from pharmacokinetic studies in
healthy volunteers and animal models was used to deter-
mine the optimal dosing regimen for ceftobiprole in
patients with HAP or CAP [22, 59]. However, individual
variations in pharmacokinetics may complicate calculation
of the optimal dosing regimen. Monte Carlo simulations
are therefore considered a valuable method for assessing
the probability of achieving defined pharmacodynamic
target values with different dosing regimens based on
population pharmacokinetic modelling data [60, 61]. In an
initial simulation, pharmacokinetic data from individuals
involved in the multiple ascending dose, phase I clinical
study were used for the population pharmacokinetic mod-
elling [22], with ceftobiprole concentrations in plasma
predicted using a two-compartment model. The analyses
examined the effects of different dosing regimens on target
attainment for %fT[MIC of 30–60 % across a range of
MIC values (1–16 mg/L). Ceftobiprole 500 mg every 8 h
showed a probability of target attainment (PTA) of 100 %
for %fT[MIC of 30 and 40, and 99 % for %fT[MIC of
50 % at an MIC of 4 mg/L, and a PTA of 100 % for
%fT[MIC of 50 and 60 % at an MIC of 2 mg/L [22],
although it should be acknowledged that this simulation
was based on data from a relatively small number of
healthy individuals (n = 12).
A subsequent modelling analysis examined the effect of
lung penetration of ceftobiprole (as measured by ELF
concentrations) on the exposure targets required for valid
antimicrobial activity in a murine model of S. aureus
pneumonia [41]. In this model, the %fT[MIC for cefto-
biprole in ELF to kill 1 log10 and 2 log10 colony-forming
units (CFU)/g of lung tissue were 13 and 24 %, respec-
tively [41]. This is noteworthy, given that b-lactam agents
may differ in their penetration into lung tissue [43], and
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drug concentration at the site of infection may be an
important factor in determining treatment outcome; this
mixed analysis could therefore provide additional data for
the optimal ceftobiprole dose to be used for the treatment
of pneumonia in humans [41]. On the basis of the cell kill
targets identified in the pneumonia model, as well as data
from population pharmacokinetic modelling of cefto-
biprole in healthy volunteers, Monte Carlo simulations
were used to determine the target attainment rate [calcu-
lated as the cumulative fraction of predicted response
(CFR)] for a 2-h infusion of ceftobiprole 500 mg every 8 h
using the MIC distribution for ceftobiprole for over 4950
MRSA isolates. The findings showed that the CFR for ELF
against MRSA in humans was 85.6 % for a 1 log10 CFU/g
kill, and 79.7 % for a 2 log10 CFU/g kill [41].
A further simulation study used pharmacokinetic data
from 150 individuals included in phase I and phase II trials
[59]. The main parameters for ceftobiprole were estab-
lished using population pharmacokinetic modelling, with
Monte Carlo simulations applied to determine the PTA
with ceftobiprole 500 mg every 8 h, administered as
30-min, 1- or 2-h infusions, for %fT[MIC values of
30–60 % at different MICs (0.25–8 mg/L). Target attain-
ment was determined for different rates of creatinine
clearance (CLCR). At normal CLCR values (80–120 mL/
min), the PTA with ceftobiprole 500 mg every 8 h,
administered as a 2-h infusion, was at least 96 % for a
%fT[MIC of 30 %, and at least 80 % for %fT[MIC of
50 % at an MIC of B4 mg/L (Table 2) [59].
Additional analyses examined the target attainment for
specific organisms, based on ceftobiprole MIC data
obtained from either surveillance programmes or cefto-
biprole clinical studies [59]. As the authors state, these
showed that a 2-h infusion of ceftobiprole 500 mg every
8 h had an estimated target attainment of [90 % for
%fT[MIC of 50 % across the whole range of MRSA and
methicillin-susceptible S. aureus (MSSA) isolates at a MIC
of 0.5 and 1 mg/L, respectively. The same ceftobiprole
regimen also showed a good estimated target attainment
against Gram-negative susceptible pathogens [59]. How-
ever, it is not entirely clear whether the authors calculated a
PTA based on an epidemiological cut-off (ECOFF) value
for a specific population, or whether they calculated the
CFR.
Taken together, data from Monte Carlo analyses carried
out among healthy volunteers demonstrate that ceftobiprole
500 mg infused over a 2-h period every 8 h is the optimal
regimen to provide adequate coverage against pathogens
with an MIC of B4 mg/L.
Modelling analyses were also used to determine the
actual observed target attainment (OTA) with ceftobiprole
500 mg administered over a 2-h period every 8 h among
patients with HAP enrolled in a phase III study [62]. A
population model was used to calculate individual expo-
sures to ceftobiprole for study populations based on either
covariates or patient samples. The OTA in both groups was
then determined for different %fT[MIC targets at a range
of MIC values. The analysis showed an attainment of
higher than 90 % for %fT[MIC of up to 70 % in patients
with HAP for MIC values up to 4 mg/L. Interestingly, it is
notable that Monte Carlo simulations based on data from
healthy individuals might be adequate in predicting actual
exposure to ceftobiprole among this study population [62].
A further analysis was performed using these data to
determine the potential effects of augmented clearance on
ceftobiprole concentrations among the study population.
Pharmacokinetic parameter estimates for each patient were
used to determine the %fT[MIC at 4 mg/L for patients
with known ceftobiprole plasma concentrations (n = 52),
as well as for the overall patient group, based on CLCR
values (n = 391) and the population model [62]. Figure 1
shows the %fT[MIC at an MIC of 4 mg/L as a function
of CLCR for both groups. The majority of patients had a
%fT[MIC above 50 % (stasis target) or 60 % (1-log kill
target), although high clearance rates suggested that some
patients may have been underexposed.
In a further Monte Carlo simulation based on the pop-
ulation of patients with HAP from the phase III study, the
antimicrobial activity of ceftobiprole 500 mg (adminis-
tered over a 2-h period every 8 h) against MRSA isolates
from ICUs was compared with that for other anti-MRSA
antimicrobial agents used at standard doses (dalbavancin
Table 2 Probabilities of target attainment with ceftobiprole 500 mg administered as a 2-h infusion every 8 h [59]
Creatinine clearance (mL/min) Probability of target attainment (%)
30 % fT[MIC for MIC (mg/L)
of:
40 % fT[MIC for MIC (mg/L)
of:
50 % fT[MIC for MIC (mg/L)
of:
0.5 1 2 4 0.5 1 2 4 0.5 1 2 4
80 99 99 99 98 99 99 99 94 99 98 97 89
100 99 99 99 97 99 99 98 92 99 98 95 85
120 99 99 99 96 99 99 97 89 99 98 94 80
MIC minimum inhibitory concentration, fT[MIC time free (unbound) drug concentration is above MIC
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1000 mg, daptomycin 4 or 6 mg/kg/day, tigecycline 50 mg
every 12 h, linezolid 600 mg every 12 h, and vancomycin
1 or 1.5 g every 12 h) [63]. Ceftobiprole, together with
dalbavancin, was found to have the highest CFR for the
pharmacokinetic/pharmacodynamic target against MRSA,
and provides optimal coverage up to the EUCAST non-
species-specific breakpoint MIC of 4 mg/L.
The relationship between ceftobiprole exposure and
microbiological eradication at the end of therapy (EOT)
was also evaluated using data from the phase III study of
patients with HAP [64]. Of note, pharmacokinetic/phar-
macodynamic analysis showed that %fT[MIC (based on
the highest observed MIC of any pathogen cultured at
baseline and/or the EOT) was the most significant predictor
of microbiological eradication at the EOT (p\ 0.0001) in
multiple logistic regression analysis. Moreover, univariate
analysis showed a significant correlation between
%fT[MIC and microbiological eradication at the EOT.
Furthermore, %fT[MIC was also a significant predictor
of clinical cure at the TOC visit (p = 0.0062) [64].
5 Pharmacokinetics and Dosing of Ceftobiprole
in Special Patient Populations
As noted above, the approved dose of ceftobiprole in adults
with normal renal function is 500 mg, administered as a
2-h intravenous infusion every 8 h [14]. Ceftobiprole has
been shown to be generally well tolerated at doses of up to
1000 mg every 8 h [25]. However, there is a need for dose
adjustment in patients with moderate or severe renal
impairment or end-stage renal disease (ESRD) [14], and
additional patient-related factors should also be considered
when selecting an appropriate regimen.
5.1 Patients with Renal Impairment
The pharmacokinetics of ceftobiprole are affected by renal
impairment, consistent with its predominantly renal
excretion through glomerular filtration [13]. A study
compared the pharmacokinetic parameters following a
single 30-min intravenous infusion of ceftobiprole 250 mg
in healthy individuals with normal renal function and those
with differing degrees of renal impairment (Table 3)
[51, 65]. Systemic exposure increased linearly with the
severity of renal impairment; t was also increased in
individuals with reduced renal function, particularly in
those with severe impairment. Total CLR decreased with
decreasing renal function, and marked reductions were
observed with moderate (80 %) and severe (91 %)
impairment, when compared with normal renal function,
although it should be noted that there were only small
numbers of individuals in each group (Table 3) [51]. Sys-
temic and renal clearance showed a good linear correlation
with CLCR (correlation coefficient = 0.9858 and 0.9871,
respectively) (Fig. 2), confirming that dose modification of
ceftobiprole in patients with renal impairment can be
accurately predicted on the basis of CLCR.
A study in patients with ESRD requiring dialysis
showed that systemic exposure to ceftobiprole [in terms
of AUC from time zero to infinity (AUC?)] was 3.2-fold
higher than in healthy individuals when ceftobiprole
was administered pre-dialysis, and approximately seven-
fold higher when it was administered post-dialysis
(Table 3) [65]. In addition, systemic clearance was mark-
edly reduced in patients with ESRD compared with healthy
individuals, while t was approximately sevenfold longer,
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Fig. 1 Percentage of time the plasma drug concentration is above the
MIC (%fT[MIC) at 4 mg/L: Monte Carlo simulations for patients
in the HAP study. a %fT[MIC determined based on the population
model and actual ceftobiprole plasma concentrations (n = 52);
b %fT[MIC calculated based on creatinine clearance as a covariate
in the overall patient population (n = 391). MIC minimum inhibitory
concentration, HAP hospital-acquired pneumonia
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although, as with the renal impairment study, the number
of participants was small (Table 3). The estimated mean
extraction ratio of ceftobiprole during a 4-h dialysis was
0.685, and mean dialysis clearance was 7.91 L/h [65].
Consistent with these findings, dose adjustment is rec-
ommended for ceftobiprole in patients with moderate or
severe renal impairment [14]. In those with moderate
impairment (CLCR 30 to\50 mL/min), the recommended
dose is 500 mg, administered as a 2-h intravenous infusion
every 12 h, whereas for those with severe impairment
(CLCR \30 mL/min) the recommended dose is 250 mg,
administered as a 2-h intravenous infusion every 12 h. For
patients with ESRD, the recommended dose is 250 mg
once every 24 h, regardless of haemodialysis application
[14]. Similar to ceftobiprole, other cephalosporins used in
the treatment of HAP or CAP have been shown to require
Table 3 Main pharmacokinetic parameters following a single intravenous infusion of ceftobiprole in healthy individuals and those with renal
impairment or end-stage renal disease requiring dialysis [51, 65]
Parameter Renal impairment studya ESRD studyb
Normal Mild Moderate Severe Healthy Pre-dialysis Post-dialysis
CLCR[ 80
mL/min
CLCR 50–80
mL/min
CLCR 30
to\ 50
mL/min
CLCR\ 30
mL/min
[n = 5] [n = 5] [n = 5] [n = 5] [n = 6] [n = 5] [n = 5]
Cmax (mg/L) 20.6 ± 2.06 20.1 ± 1.45 24.4 ± 1.65 22.8 ± 3.48 11.1 ± 1.77 13.3 ± 2.33 21.1 ± 14.7
AUClast (mgh/L) 52.4 ± 6.95 72.7 ± 13.9 139 ± 15.7 174 ± 44.5 44.3 ± 7.12 118 ± 8.73 249 ± 49.0
AUC? (mgh/L) 52.8 ± 6.91 74.8 ± 15.6 151 ± 21.6 222 ± 71.0 45.2 ± 6.84 143 ± 8.53 311 ± 75.1
t (h) 3.45 ± 0.37 4.75 ± 0.81 6.87 ± 1.12 11.1 ± 1.96 3.0 ± 0.4 20.7 ± 1.83 20.5 ± 5.33
VSS (L) 15.8 ± 1.81 18.0 ± 0.76 14.2 ± 0.80 16.9 ± 2.39 24.4 ± 3.68 52.5 ± 5.23 23.9 ± 5.14
CLT (L/h) 4.80 ± 0.61 3.46 ± 0.71 1.68 ± 0.25 1.21 ± 0.36 5.62 ± 0.73 1.76 ± 0.10 0.845 ± 0.21
CLR (L/h) 4.38 ± 0.51 2.48 ± 0.63 0.88 ± 0.25 0.41 ± 0.24 5.11 ± 0.81 NC NC
Urinary recovery (%) 91.6 ± 6.55 71.1 ± 7.32 51.9 ± 9.93 31.5 ± 9.65 88.6 ± 4.06 NC NC
Data are expressed as mean ± standard deviation
AUC area under the plasma concentration–time curve, AUClast AUC from time zero to the last measurable concentration, AUC? AUC from time
zero extrapolated to infinity, Cmax maximum plasma concentration, CLCR creatinine clearance, CLR renal clearance, CLT total systemic clearance,
ESRD end-stage renal disease, NC not calculated, t elimination half-life, VSS volume of distribution at steady state
a Ceftobiprole 250 mg administered as a 30-min infusion
b Ceftobiprole 250 mg administered as a 120-min infusion
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Fig. 2 Correlation between
creatinine clearance and
systemic and renal clearance
following a single intravenous
infusion of ceftobiprole 250 mg
over 30 min in individuals with
normal renal function and those
with renal impairment [51].
Data are shown for individuals
with normal renal function
(CLCR[80 mL/min; n = 5)
and those with mild (CLCR
50–80 mL/min; n = 5),
moderate (CLCR 30 to\50 mL/
min; n = 5) or severe (CLCR
\30 mL/min; n = 5) renal
impairment. CLCR creatinine
clearance
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dose adjustments in patients with renal impairment. For
ceftaroline, dose reductions are recommended for patients
with moderate-severe impairment and those with ESRD
[30]. Similar adjustments are also recommended for cefe-
pime [66] and ceftazidime [67].
5.2 Treatment in Critically Ill Patients
Pathophysiological changes are common in critically ill
patients, which could affect the pharmacokinetics of
antibiotics [68, 69]. A systematic review of pharmacoki-
netic studies assessing intravenous b-lactam antibiotics in
infected patients treated in the ICU reported significant
changes in the pharmacokinetics of all six of the agents
studied [70]. Increased capillary permeability as a result of
infection can lead to the movement of fluid to the inter-
stitial space, thus increasing the volume of distribution of
hydrophilic drugs such as b-lactam antibiotics, and
decreasing their plasma concentration. In addition,
increases in renal perfusion are often observed in these
patients, leading to higher CLCR and increased elimination
of hydrophilic drugs [68, 69]. Patients with augmented CLR
may therefore require higher maintenance doses of
hydrophilic antibiotics through more frequent administra-
tions and/or longer or even continuous infusions in order to
maintain adequate therapeutic exposure to the antimicro-
bial agent [69].
A recent open-label study carried out in 33 adults treated
in the ICU examined the pharmacokinetics of high-dose
ceftobiprole administered over a longer infusion period
(1000 mg over 4 h) [71]. The frequency of administration
was chosen on the basis of CLCR measurements (every 8 h
in those with CLCR[80 mL/min and every 12 h in those
with CLCR 50–79 mL/min). Blood samples for pharma-
cokinetic analysis were collected during the morning dose
of day 2 [71]. Systemic clearance of ceftobiprole was
higher for patients with high CLCR ([150 mL/min) than
for those with normal (80–100 mL/min) or low CLCR
(50–79 mL/min), with a twofold difference between the
high and low clearance groups (Table 4) [71]. However,
the analysis included only small numbers of patients with
high and low CLCR (six and five patients, respectively),
which represents a potential limitation of the study. Further
analysis of these patients showed that mechanical ventila-
tion had no consistent effects on the pharmacokinetics of
ceftobiprole, although the number of ventilated patients in
each group was low. Pharmacodynamic analysis demon-
strated that prolongation of the infusion time to 4 h was
sufficient to provide plasma levels of ceftobiprole above
the EUCAST non-species-specific breakpoint MIC of
4 mg/L for the entire dosing interval, even among patients
in the ICU with CLCR[150 mL/min [71]. In patients with
high CLCR, fT[MIC for ceftobiprole 1000 mg was
reduced compared with patients with normal or low CLCR
(Table 5). However, ceftobiprole 1000 mg every 8 h
allowed maintenance of plasma free concentrations above
the MIC for the entire dosing interval (%fT[MIC[ 100).
By extrapolating these findings to a 500 mg dose, the
%fT[MIC for ceftobiprole among patients with high
CLCR was 91 % (Table 5) [71]. Therefore, extending the
infusion time to 4 h may help optimize drug exposure
when standard doses of ceftobiprole 500 mg every 8 h are
administered to patients with augmented CLR (CLCR
[150 mL/min) [14]. The findings of this study are con-
sistent with the Monte Carlo simulations assessing the
effects of augmented clearance on ceftobiprole concentra-
tions (as discussed in Sect. 4). High CLR (e.g. among the
critically ill) might contribute to a lower %fT[MIC in
some patients. However, a previous ceftobiprole Monte
Carlo simulation has demonstrated that, while high CLR
contributes to low exposure in the subpopulation, not all
patients with high CLCR have low exposure to ceftobiprole,
reflecting the inaccuracy of CLCR estimates as a surrogate
for CLR [62]. Moreover, data for target attainment derived
from healthy individuals predicted exposure in a patient
population, including those who are severely ill [62].
5.3 Paediatric Patients
A recent open-label study evaluated the pharmacokinetics
of a single dose of ceftobiprole in 55 paediatric patients
(aged 3 months to\18 years) requiring systemic antibi-
otics [72]. Ceftobiprole was administered as a 2-h infusion,
with doses adjusted to achieve exposures equivalent to
those in adults following standard dosing (15 mg/kg for
patients aged 3 months to\2 and 2 to\6 years; 10 mg/kg
for those aged 6 to\12 years; and 7 mg/kg for individuals
aged 12 to \18 years). Ceftobiprole pharmacokinetic
parameters in paediatric patients were broadly within the
range of those reported for adults [15, 26]. Ceftobiprole
exposure was up to 20 % lower in patients aged\12 years
(mean ± SD: Cmax 24.4 ± 9.1 to 28.7 ± 7.0 lg/mL;
AUC? 79.5 ± 16.2 to 87.7 ± 28.2 lgh/mL) than in
adults (Cmax 29.2 ± 5.5 lg/mL; AUC?104 ± 13.9 lgh/
mL), and approximately 40 % lower in patients aged 12 to
\18 years (Cmax 17.4 ± 3.2 lg/mL; AUC?
63.5 ± 14.3 lgh/mL) than in adults [72]. When adjusted
for body weight, volume of distribution and total clearance
decreased with increasing age in paediatric patients,
whereas CLR and t (not adjusted for body weight) were
similar across the age groups. In paediatric patients,
ceftobiprole concentrations remained above the target MIC
of 4 mg/L for 66.5 to 75.3 % of an 8-h time period
(%T[MIC), and ceftobiprole treatment was generally
well tolerated [72]. The lower ceftobiprole exposure
observed in patients aged 12 years to\18 years compared
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with adults has implications for the design of future studies
in paediatric patient populations. Ceftobiprole is currently
not approved for use in paediatric patients.
5.4 Patients with Severe Obesity
Patients who are obese may have physiological alterations
that influence the pharmacokinetics of drugs. An open-la-
bel, single-centre study compared the pharmacokinetics of
a single intravenous infusion of ceftobiprole 500 mg over
2 h in adults who were severely obese [body mass index
(BMI)][40 kg/m2) and those who were not obese (BMI
18–30 kg/m2) [73]. Mean BMI was 45.5 kg/m2 in the
severely obese group (n = 12) compared with 24.0 kg/m2
in the non-obese group (n = 13); other baseline charac-
teristics were similar in the two groups. Volume of distri-
bution and total clearance of ceftobiprole were 25.9 and
19.1 % higher, respectively, in severely obese than non-
obese individuals (Table 6) [73]. Ceftobiprole exposure
was lower in severely obese adults than in those who were
not obese. Plasma concentrations of unbound ceftobiprole
remained above the target MIC of 4 mg/L (fT[MIC) for
76.6 and 79.7 % of an 8-h dosing interval in severely obese
and non-obese individuals, respectively [73]. Although
volume of distribution and total clearance were higher, and
exposure was lower, in severely obese adults compared
with non-obese individuals (Table 6) following a single
ceftobiprole infusion, %fT[MIC was similar in the two
groups, indicating that there is no need for dose adjustment
of ceftobiprole in severely obese patients.
5.5 Patients with Ventilator-Associated Pneumonia
In the phase III HAP study, ceftobiprole 500 mg, admin-
istered as a 2-h infusion every 8 h, did not demonstrate
non-inferiority to ceftazidime 2 g every 8 h/linezolid
600 mg every 12 h in the subgroup of VAP patients [19].
The clinical cure rates at the TOC visit were lower with
ceftobiprole than with ceftazidime/linezolid in the intent-
to-treat (ITT; 23.1 vs. 36.8 %) and clinically effective (CE;
37.7 vs. 55.9 %) populations. A similar pattern of results
was seen with microbiological eradication rates at TOC
Table 4 Main pharmacokinetic
parameters for high-dose
ceftobiprole administration in
intensive care unit patients,
according to creatinine
clearance [71]
Parameter Lowa Normalb Highb
CLCR 50–79 mL/min CLCR 80–150 mL/min CLCR[150 mL/min
[n = 5] [n = 20] [n = 6]
Cmax (mg/L) 51.6 ± 11.2 37.8 ± 7.3 27.6 ± 7.3
tmax (h) 4.7 (3.4–6.0) 4.0 (3.5–4.5) 3.9 (3.5–4.0)
AUClast (mgh/L) 405 ± 93.2 269 ± 116 180 ± 75.3
t (h) 4.5 ± 1.0 3.8 ± 1.6 3.8 ± 1.2
VSS (L) 23.7 ± 6.6 23.1 ± 6.3 29.4 ± 7.5
CLT (L/h) 3.8 ± 0.6 5.2 ± 1.2 7.4 ± 1.5
Protein binding (%) 19.1 ± 4.4 20.5 ± 7.3 21.6 ± 3.5
Data are expressed as mean ± standard deviation, except for tmax, which is expressed as median (range)
AUClast area under the plasma concentration–time curve from time zero to the last measurable concen-
tration, Cmax maximum plasma concentration, CLCR creatinine clearance, CLT total systemic clearance, t
elimination half-life, tmax time to Cmax, VSS volume of distribution at steady state
a Ceftobiprole 1000 mg administered as a 4-h infusion every 12 h
b Ceftobiprole 1000 mg administered as a 4-h infusion every 8 h
Table 5 Pharmacodynamic analysis of ceftobiprole treatment in patients treated in the intensive care unit [71]
Ceftobiprole 1000 mg (observed) Ceftobiprole 500 mg (extrapolated)
CLCR
50–79 mL/min
CLCR
80–150 mL/min
CLCR[150 mL/min CLCR
80–150 mL/min
CRCR[150 mL/min
T[MICa (h) 19.6 ± 4.1 14.5 ± 6.0 12.0 ± 5.0 – –
fT[MICa (h) 18.2 ± 4.0 13.2 ± 5.5 10.8 ± 5.2 9.5 ± 4.3 7.3 ± 3.9
%fT[MICa (q8 h) [100 [100 [100 [100 91
Data are expressed as mean ± standard deviation, unless otherwise stated
CLCR creatinine clearance, MIC minimum inhibitory concentration, T[MIC time the plasma drug concentration is above the MIC, fT[MIC
time the free (unbound) drug concentration is above the MIC, q8 h every 8 h
a MIC = 4 mg/L
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[19]. All-cause mortality at 30 days in patients with VAP
was 26.9 % for ceftobiprole and 19.8 % for cef-
tazidime/linezolid; 30-day pneumonia-specific mortality
was similar in the two groups (ceftobiprole 8.7 %; cef-
tazidime/linezolid 7.5 %) [19]. Furthermore, bacteriologi-
cal eradication at the EOT was found to be similar in
patients with or without VAP [64], and Monte Carlo sim-
ulations have demonstrated that the PTA in patients with
VAP is no different from that in those without VAP [62].
Although the peculiar pathophysiological status might
account for this, an analysis of the subgroup of mechani-
cally ventilated patients with HAP who did not have VAP
suggested that ventilation itself did not affect these out-
comes. In these patients, clinical cure rates with cefto-
biprole were similar to those with ceftazidime/linezolid in
the ITT population (30.4 vs. 27.1 %), and were higher in
the CE population (55.3 vs. 40.5 %) [19]. Multivariate
analysis of the VAP subgroup did not identify any specific
patient factor or combination of factors that could account
for the differences in treatment outcomes between the two
groups [19]. Furthermore, the OTA in patients with VAP is
similar to that in those without VAP, and bacterial eradi-
cation at EOT is also similar between the two groups
[62, 64]. Interestingly, augmented renal function (CLCR
[150 mL/min) did not correlate with the observed find-
ings, suggesting that the data observed in patients with
VAP might reflect the heterogeneous nature of this popu-
lation [19]. Ceftobiprole is not licensed for the treatment of
VAP.
5.6 Other Patient Populations
There is no need for dose adjustment of ceftobiprole in
patients with hepatic impairment as the drug undergoes
minimal hepatic metabolism and its pharmacokinetics are
unlikely to be affected by reduced hepatic function [14].
Likewise, there is no need for dose adjustment based on sex
or ethnicity, or in elderly patients [14]. Regarding sex, one
pharmacokinetic study in healthy individuals showed that
after a single 30-min infusion of ceftobiprole 750 mg, the
AUC? was higher (15 %) and both systemic clearance and
volume of distribution were lower (12 and 29 %, respec-
tively) in women compared with men [15]; however, the
differences were no longer apparent after the parameters
were adjusted for body weight or %T[MIC. For ethnic-
ity, a study comparing the pharmacokinetics of single- and
multiple-dose ceftobiprole regimens in healthy Japanese
men demonstrated that no difference in ceftobiprole dis-
position existed compared with historical data from Cau-
casian individuals; this was also confirmed in a population
analysis [65]. Finally, with regard to age, a population
analysis used to assess the effect of age on the pharma-
cokinetics of ceftobiprole showed that CLT was typically
lower in elderly individuals than in younger individuals
[65]. However, age was not a statistically significant
covariate in the final population pharmacokinetic model, in
which lower CLCR in the elderly explained the lower sys-
temic clearance of ceftobiprole [65]. Therefore, no specific
ceftobiprole dose adjustments are required based on age
alone, except in cases of moderate and severe renal
impairment, as recommended for the general population
[14].
6 Limitations
The studies reporting the pharmacokinetics of ceftobiprole
do, however, have some limitations. Evaluation of cefto-
biprole pharmacokinetics in individuals with renal
impairment and those with ESRD involved only limited
numbers of subjects in each assessment group. Similarly,
although overall patient numbers were larger in the study
Table 6 Main pharmacokinetic
parameters following a single
intravenous infusion of
ceftobiprole in patients who
were severely obese and those
who were not obese [73]
Severely obese [n = 11]a Non-obese [n = 13]
Cmax (lg/mL) 21.4 ± 3.0 30.2 ± 4.3
AUC? (lgh/mL) 91.0 ± 11.7 110 ± 20.1b
t (h) 3.4 ± 0.3 3.2 ± 0.5
b
Vdz (L) 27.2 ± 3.9 21.6 ± 5.1
b
CL (L/h) 5.6 ± 0.7 4.7 ± 0.7b
%fT[MIC (4 mg/L)c 76.6 ± 9.2c 79.7 ± 7.3
Data are expressed as mean ± standard deviation
AUC? AUC from time zero extrapolated to infinity, Cmax maximum plasma concentration, CL clearance,
MIC minimum inhibitory concentration, T[MIC time the plasma drug concentration is above the MIC, t
elimination half-life, Vdz volume of distribution
a One subject who received treatment was excluded from the pharmacokinetic analysis
b n = 12
c 8-h dosing interval
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of adults treated in the ICU, the number of patients with
augmented CLR was small. The pharmacokinetic mod-
elling data used in Monte Carlo simulations to determine
the optimal ceftobiprole dosing regimen were based on
data from healthy volunteers, an approach that it has been
suggested may not accurately reflect the pharmacokinetics
observed in patients. However, the value of this approach
has been supported by a study comparing modelled phar-
macokinetic data from healthy volunteers with actual
ceftobiprole exposure data in patients with HAP; this
analysis clearly demonstrated that the Monte Carlo simu-
lations adequately predicted actual exposure to ceftobiprole
in this patient population [62]. Future pharmacokinetic/
pharmacodynamic studies in patients with HAP and CAP
would prove valuable, given the limited pharmacokinetic
data currently available from these patients, especially in
patients with VAP.
7 Summary
Ceftobiprole is a new-generation, broad-spectrum cepha-
losporin that has recently been approved for the treatment of
HAP (excluding VAP) and CAP [11]. It shows antimicrobial
activity in vitro against a broad range of Gram-positive and
Gram-negative pathogens important in pneumonia, includ-
ing MRSA [11, 16]. The prodrug ceftobiprole medocaril is
rapidly and almost completely converted to the active sub-
stance, ceftobiprole, following intravenous infusion
[23, 24]. The efficacy of ceftobiprole 500 mg, infused over
2 h every 8 h, has been demonstrated in two randomized,
double-blind, phase III clinical studies carried out among
patients with HAP (excluding VAP) or CAP [19, 20].
Ceftobiprole exhibits linear pharmacokinetics over the
dose range 125–1000 mg [23, 24], and steady-state con-
centrations are rapidly attained on the first day of dosing
[14]. The elimination of ceftobiprole occurs predominantly
through renal excretion. Therefore, prolongation of infu-
sion time is recommended for patients with augmented
renal clearance, whereas dose reductions are recommended
for those with moderate or severe renal impairment and for
patients with ESRD, irrespective of dialysis application
[14]. A study in critically ill patients showed that the
systemic clearance of ceftobiprole was increased in
patients with augmented CLR; extending the infusion time
of the standard 500 mg dose of ceftobiprole to 4 h may
therefore help to optimize drug exposure in these patients.
There is no need for dose adjustment based on sex, eth-
nicity, age or hepatic impairment [14].
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